{"id":545,"date":"2012-02-28T12:16:25","date_gmt":"2012-02-28T16:16:25","guid":{"rendered":"http:\/\/www.hnetalk.com\/Member\/?p=545"},"modified":"2012-02-28T12:16:25","modified_gmt":"2012-02-28T16:16:25","slug":"generic-version-of-lipitor-now-available","status":"publish","type":"post","link":"https:\/\/hnetalk.com\/member\/generic-version-of-lipitor-now-available\/","title":{"rendered":"Generic Version of Lipitor\u00ae Now Available"},"content":{"rendered":"<p>At HNE we are constantly looking for ways to keep down health care costs, while continuing to provide you with the highest possible level of quality. As part of this commitment, atorvastatin, the generic formulation of Lipitor\u00ae, will be categorized as a Tier 1 medication on the HNE formulary. It will be available without prior approval to members currently receiving Lipitor\u00ae. HNE will require prior approval of atorvastatin for all other members, including those with a history of simvastatin or pravastatin use.<\/p>\n<p>We have provided a summary of the tier status and member copayment for the most commonly prescribed cholesterol-lowering medications (see chart on right). The copayment will vary by your benefit package.<\/p>\n<p>If you have any questions, please contact <strong>Member Services<\/strong> at <strong>413.787.4004<\/strong> or <strong>800.310.2835.<\/strong><\/p>\n<table width=\"449\" border=\"1\" cellspacing=\"0\" cellpadding=\"8\">\n<tbody>\n<tr>\n<td align=\"center\" bgcolor=\"#99CCFF\">Medication<\/td>\n<td align=\"center\" bgcolor=\"#99CCFF\">Status<\/td>\n<td align=\"center\" bgcolor=\"#99CCFF\">Member<br \/>\nCopayment<\/td>\n<td align=\"center\" bgcolor=\"#99CCFF\">Approximate<br \/>\n30-day<br \/>\nSupply Cost*<\/td>\n<td align=\"center\" bgcolor=\"#99CCFF\">Prior<br \/>\nAuthorization<br \/>\nRequired<\/td>\n<\/tr>\n<tr>\n<td align=\"left\">Simvastatin<br \/>\n20\/40 mg<\/td>\n<td align=\"center\">Tier 1<\/td>\n<td align=\"center\">\u2264 $15<\/td>\n<td align=\"center\">$10.70<\/td>\n<td align=\"center\">No<\/td>\n<\/tr>\n<tr>\n<td align=\"left\">Pravastatin<br \/>\n20\/40 mg<\/td>\n<td align=\"center\">Tier 1<\/td>\n<td align=\"center\">\u2264 $15<\/td>\n<td align=\"center\">$9.73**<\/td>\n<td align=\"center\">No<\/td>\n<\/tr>\n<tr>\n<td align=\"left\">Lipitor\u00ae<br \/>\n20\/40 mg<\/td>\n<td align=\"center\">Tier 3<\/td>\n<td align=\"center\">\u2264 $100<\/td>\n<td align=\"center\">$163.34<\/td>\n<td align=\"center\">Yes<\/td>\n<\/tr>\n<tr>\n<td align=\"left\">Atorvastatin<br \/>\n20\/40 mg<\/td>\n<td align=\"center\">Tier 1<\/td>\n<td align=\"center\">\u2264 $15<\/td>\n<td align=\"center\">$141.39<\/td>\n<td align=\"center\">Yes***<\/td>\n<\/tr>\n<tr>\n<td align=\"left\">Crestor\u00ae<br \/>\n20\/40<br \/>\n(rosuvastatin)<\/td>\n<td align=\"center\">Tier 2<\/td>\n<td align=\"center\">\u2264 $50<\/td>\n<td align=\"center\">$140.00<\/td>\n<td align=\"center\">Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>* When a patent expires, the first company to file for a generic version of the medication gets six<br \/>\nmonths\u2019 exclusive rights to sell this product. During this time, the price of the drug is decreased<br \/>\nby only 10 percent. At the end of the exclusivity period, it is anticipated that atorvastatin will<br \/>\nbe available from additional manufacturers at a reduced cost.<br \/>\n** May be available at a reduced price through various retail prescription drug programs.<br \/>\n*** Not required for members with a previously approved prior authorization for Lipitor.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At HNE we are constantly looking for ways to keep down health care costs, while continuing to provide you with the highest possible level of quality. As part of this commitment, atorvastatin, the generic formulation of Lipitor\u00ae, will be categorized as a Tier 1 medication on the HNE formulary. It will be available without prior [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[28],"tags":[],"class_list":["post-545","post","type-post","status-publish","format-standard","hentry","category-winter-2012"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p6ZZGa-8N","_links":{"self":[{"href":"https:\/\/hnetalk.com\/member\/wp-json\/wp\/v2\/posts\/545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hnetalk.com\/member\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hnetalk.com\/member\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hnetalk.com\/member\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hnetalk.com\/member\/wp-json\/wp\/v2\/comments?post=545"}],"version-history":[{"count":0,"href":"https:\/\/hnetalk.com\/member\/wp-json\/wp\/v2\/posts\/545\/revisions"}],"wp:attachment":[{"href":"https:\/\/hnetalk.com\/member\/wp-json\/wp\/v2\/media?parent=545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hnetalk.com\/member\/wp-json\/wp\/v2\/categories?post=545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hnetalk.com\/member\/wp-json\/wp\/v2\/tags?post=545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}